Institut Curie;Institut National de la Santé et de la Recherche Médicale (INSERM)
发明人:
申请号：
EP18778409.5
公开号：
EP3684410A1
申请日:
2018.09.19
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present invention relates to an AhR agonist for use in combination with at least one immune checkpoint modulator in the treatment of cancer. The present invention also encompasses product containing an AhR agonist and at least one immune checkpoint modulator as defined in any one of the preceding claims, as a combined preparation for simultaneous, separate or sequential use in the treatment of cancer.
